Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Reducing Adverse Events Through Dose Optimization

October 25th 2022

Tanios S. Bekaii-Saab, MD, discusses minimizing the toxicities associates with tyrosine kinase inhibitors (TKIs) through dose optimizations strategies, which are of particular interest at TKIs are combined with immune checkpoint inhibitors that also may impact the liver.

Vigilance Is Key in Mitigating TKI-Associated Hepatotoxicity

October 25th 2022

Liver injury can occur within 2 weeks of starting therapy with a tyrosine kinase inhibitor, although it can also be seen as late as 2 months, describes Tanios S. Bekaii-Saab, MD, making vigilance key for proper mitigation of this adverse event.

FDA Approves Durvalumab/Tremelimumab in Unresectable HCC

October 24th 2022

The FDA has approved durvalumab (Imfinzi) in combination with tremelimumab (Imjudo) for the treatment of adult patients with unresectable hepatocellular carcinoma.

Targeting Transcription as a New Frontier in Advanced Pancreatic Cancer

October 21st 2022

A new focus of research has reconsidered the mechanisms in regulating transcription as a novel target for advanced pancreatic ductal adenocarcinoma.

Real-World Use of First-Line Lenvatinib Therapy in Advanced HCC

October 21st 2022

Comprehensive discussion on the real-world applications of first-line lenvatinib therapy in advanced HCC followed by its potential in combination with TACE.

Advanced HCC: Clinical Trial Data Behind First-Line Therapy Options

October 21st 2022

Expert oncologists take a look at clinical trial data as they pertain to prevalent first-line systemic therapy options in advanced hepatocellular carcinoma.

FDA Grants Fast Track Designation to TTI-101 for Advanced Hepatocellular Carcinoma

October 19th 2022

The FDA has granted a fast track designation to TTI-101 for the treatment of patients with relapsed/refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma.

Advanced Biliary Tract Cancers: First- and Second-Line Chemotherapy

October 19th 2022

Focused discussion on chemotherapy treatment options commonplace in patients with advanced or metastatic biliary tract cancers.

Futibatinib Approval Expands Options for Patients With FGFR2+ Cholangiocarcinoma

October 19th 2022

The accelerated approval of the FGFR inhibitor futibatinib on September 30, 2022, has expanded options for previously treated adult patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma FGFR2 fusions or rearrangements.1

An Overview of Systemic Therapy for Advanced Biliary Tract Cancers

October 19th 2022

Shifting their focus to the advanced disease setting, panelists provide a comprehensive overview on systemic treatment modalities used in biliary tract cancers.

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors

October 18th 2022

Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.

Understanding and Detecting TKI-Specific Hepatotoxicity

October 18th 2022

Tanios S. Bekaii-Saab, MD, describes the hepatotoxicity commonly seen with tyrosine kinase inhibitors (TKIs) and how to monitor and detect it with aspartate aminotransferase (AST) and alanine transaminase (ALT).

Overview of Toxicity Associated With TKIs in Solid Tumors

October 18th 2022

Tanios S. Bekaii-Saab, MD, describes the common adverse events associated with each type of tyrosine kinase inhibitor (TKI), which are specific to the targets hit by that TKI and commonly include fatigue and hepatotoxicity.

FDA Grants Orphan Drug Designation to ET140203 for Hepatoblastoma

October 17th 2022

The FDA has granted an orphan drug designation to ET140203 for the treatment of patients with hepatoblastoma.

Durvalumab Plus Standard-of-Care Chemotherapy Shakes Up First-line Care in Advanced Biliary Tract Cancers

October 17th 2022

Do-Youn Oh, MD, PhD, highlights the nuances of the TOPAZ-1 trial data that signal new pathways forward for investigative efforts in advanced biliary tract cancers.

Selecting the Appropriate First-Line Therapy for Advanced HCC

October 14th 2022

In the context of the first patient profile, expert panelists consider which factors play into their selection of first-line systemic agents in advanced hepatocellular carcinoma.

Patient Profile 1: A 77-Year-Old Man with Advanced HCC Treated With Lenvatinib

October 14th 2022

Focusing on the first patient profile of advanced hepatocellular carcinoma, Andrea Casadei-Gardini, MD, reviews his selection and use of first-line lenvatinib therapy.

Marshall Provides Insight on Evolving Treatment Patterns in ESCC

October 13th 2022

John L. Marshall, MD, provides an overview of esophageal squamous cell carcinoma and discusses several key updates to the treatment landscape, including putting data in the context of the treatment algorithm.

Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric Cancer

October 13th 2022

Shared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.

Novel Clinical Trials With ADCs in Gastric Cancer

October 13th 2022

Before closing out their discussion on HER2+ gastric cancer, experts review clinical trials investigating other novel ADC agents in this setting.